4D Molecular Therapeutics, Inc. (FDMT) vs Zevra Therapeutics, Inc. (ZVRA)
A side-by-side comparison of 4D Molecular Therapeutics, Inc. and Zevra Therapeutics, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
FDMT
4D Molecular Therapeutics, Inc.
$12.56HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
ZVRA
Zevra Therapeutics, Inc.
$10.73HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
Total return — FDMT vs ZVRA
growth of $100 · dividends reinvested · last 6yFDMT -68.1% (-17.3%/yr)ZVRA -28.1% (-5.3%/yr)ZVRA compounded faster over this window
FDMT ZVRA
FDMT vs ZVRA: by the numbers
- •FDMT is the larger company ($657M vs $634M market cap).
- •ZVRA is profitable (42.82% net margin) while FDMT runs a net loss (-194.74%).
- •ZVRA grew revenue faster over the past five years (36.81% vs 31.93% CAGR).
Metrics side by side
Valuation
| Metric | FDMT | ZVRA |
|---|---|---|
| P/E ratio | N/A | 11.53 |
| Forward P/E | N/A | 9.68 |
| P/S ratio | 7.14 | 4.66 |
| P/B ratio | 1.61 | 2.91 |
| EV / EBITDA | N/A | 12.11 |
| FCF yield | N/A | 5.13% |
Profitability
| Metric | FDMT | ZVRA |
|---|---|---|
| Gross margin | 91.05% | 84.52% |
| Operating margin | -187.24% | -3.98% |
| Net margin | -194.74% | 42.82% |
| ROE | -43.95% | 26.77% |
| ROIC | -44.30% | 12.93% |
Growth (annualized)
| Metric | FDMT | ZVRA |
|---|---|---|
| Revenue CAGR (5Y) | 31.93% | 36.81% |
| Total return CAGR (5Y) | -13.08% | 3.75% |
Frequently asked
- Which has grown faster, FDMT or ZVRA?
- Over the past five years, ZVRA grew revenue faster — FDMT at a 31.93% CAGR versus ZVRA at 36.81%.
- Is FDMT or ZVRA more profitable?
- ZVRA runs the higher net margin — FDMT at -194.74% versus ZVRA at 42.82%.
- How have FDMT and ZVRA total returns compared?
- Over the past 5 years, FDMT delivered -13.08% and ZVRA delivered 3.75% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Zevra Therapeutics P/E ratio4D Molecular Therapeutics ROEZevra Therapeutics ROE4D Molecular Therapeutics operating marginZevra Therapeutics operating margin4D Molecular Therapeutics revenue growthZevra Therapeutics revenue growth4D Molecular Therapeutics free cash flowZevra Therapeutics free cash flow
4D Molecular Therapeutics & Zevra Therapeutics appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.